134 related articles for article (PubMed ID: 15507542)
1. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes.
Raghavan N; Zhang D; Zhu M; Zeng J; Christopher L
Drug Metab Dispos; 2005 Feb; 33(2):203-8. PubMed ID: 15507542
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening.
Onderwater RC; Venhorst J; Commandeur JN; Vermeulen NP
Chem Res Toxicol; 1999 Jul; 12(7):555-9. PubMed ID: 10409393
[TBL] [Abstract][Full Text] [Related]
6. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
[TBL] [Abstract][Full Text] [Related]
7. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine.
Wen B; Ma L; Rodrigues AD; Zhu M
Drug Metab Dispos; 2008 May; 36(5):841-50. PubMed ID: 18238857
[TBL] [Abstract][Full Text] [Related]
8. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.
Springer D; Paul LD; Staack RF; Kraemer T; Maurer HH
Drug Metab Dispos; 2003 Aug; 31(8):979-82. PubMed ID: 12867484
[TBL] [Abstract][Full Text] [Related]
9. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
10. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
11. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.
Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
Drug Metab Dispos; 2004 Apr; 32(4):379-81. PubMed ID: 15039289
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
Obach RS; Pablo J; Mash DC
Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
[TBL] [Abstract][Full Text] [Related]
13. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.
Yu AM; Idle JR; Krausz KW; Küpfer A; Gonzalez FJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):315-22. PubMed ID: 12649384
[TBL] [Abstract][Full Text] [Related]
14. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Eur Neuropsychopharmacol; 2004 May; 14(3):199-208. PubMed ID: 15056479
[TBL] [Abstract][Full Text] [Related]
15. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
16. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine.
Sauer C; Peters FT; Schwaninger AE; Meyer MR; Maurer HH
Chem Res Toxicol; 2008 Oct; 21(10):1949-55. PubMed ID: 18778087
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
18. The 1'-hydroxylation of Rac-bufuralol by rat brain microsomes.
Coleman T; Spellman EF; Rostami-Hodjegan A; Lennard MS; Tucker GT
Drug Metab Dispos; 2000 Sep; 28(9):1094-9. PubMed ID: 10950855
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
20. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
